CorMedix Inc. to Present Candida auris Susceptibility Data at 2nd Annual Gulf Congress of Clinical Microbiology and Infectious Diseases
Berkeley Heights, NJ – October 26, 2017 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that Bruce Reidenberg, M.D., Adjunct Assistant Professor of Pharmacology at Weill Cornell Medicine will make an oral presentation titled, “Multi-Resistant Candida auris is Susceptible to Taurolidine,” at the 2nd Annual Gulf Congress of Clinical Microbiology and Infectious Diseases held November 1-4, 2017, in the Kingdom of Bahrain.
The data further highlight the potent antimicrobial activity of CorMedix’s taurolidine, based on the susceptibility of 20 distinct clinical isolates of multi-drug resistant C. auris to this non-antibiotic anti-microbial. Dr. Reidenberg’s presentation is scheduled for 3:00pm local time in Hall C of the Gulf Hotel Convention Centre.
Khoso Baluch, Chief Executive Officer of CorMedix stated, “This is a critical time for CorMedix, as we approach the interim efficacy analysis for our ongoing Phase 3 study of Neutrolin®, which leverages taurolidine as the active antimicrobial to prevent biofilm formation and bloodstream infections in patients with central venous catheters. These patients are at particular risk of developing life-threatening C. auris infection, so demonstrating taurolidine’s effectiveness against this emerging pathogen is critical for both the worldwide infectious disease community as well as the nephrology and hemodialysis communities. We are pleased to share these encouraging results with our peers at this prestigious medical meeting.”
In addition, Antony Pfaffle, M.D., CorMedix’s Chief Scientific Officer, will represent CorMedix at the world’s premier nephrology meeting, the American Society for Nephrology’s Kidney Week. Dr. Pfaffle will discuss Neutrolin and the ongoing LOCK-IT 100 Phase 3 study with renowned opinion leaders and clinical investigators in the renal scientific and medical communities. The meeting will be held October 31 – November 5, 2017, in New Orleans, LA.
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to possible uses of taurolidine, that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the possible inability to capture sufficient CRBSI events in the ongoing Phase 3 clinical trial for Neutrolin® even with the reported changes to that trial; the cost, timing and results of the ongoing and planned Phase 3 trials for Neutrolin® in the U.S. and the resources needed to commence and complete those trials; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on planned or future research, including for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel to staff our operations appropriately. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
For Investors & Media: